OHC is the first and only adult cancer group in the Cincinnati region – and among the very few independent oncology groups in the U.S. – to bring chimeric antigen receptor T-cell therapy (CAR-T) for adults with aggressive blood cancers, ushering in a new frontier in the fight against cancer.

CAR-T is one of the most exciting and promising cancer treatment breakthroughs in recent years. CAR-T has shown dramatic results in patients who had few options and little hope and are now experiencing life in remission.

CAR-T is a type of immunotherapy that stimulates the body’s immune system to fight cancer. It uses genetically engineered immune T-cells to recognize specific proteins on tumor cells.

  • Thousands of T-cells are extracted from the patient and reengineered in a lab to produce special receptors on their surface that fight and kill cancer cells.
  • The reengineered cells are multiplied until there are millions and then infused back into the patient.
  • The cells continue to then multiply on their own in the patient’s body. These cells will recognize and kill cancer cells and help guard against recurrence.

Learn how CAR-T works in this video and the infographic below:

CAR-T immunotherapy infographic

 

Eligible Patients

CAR-T provides another cancer treatment option when standard treatments are not effective. Adult patients with relapsed or refractory large B-cell lymphoma who have failed two or more types of cancer therapy may be eligible. CAR-T clinical trials may also be available for other blood cancers or solid tumors. If you are interested in CAR-T, please call OHC at 1-800-710-4674.

OHC’s Team of CAR-T Experts

  • OHC doctors are the only adult cancer experts in the region certified to offer this advanced treatment to adults.
  • OHC’s partner, the Blood Cancer Center at The Jewish Hospital – Mercy Health, is fully accredited to treat all blood cancers.
  • All staff involved in prescribing, dispensing or administering CAR-T therapy have received special training to recognize and manage treatment side effects and nervous system toxicities that may occur.
Dr. Essell, CAR-T The OHC CAR-T team is led by James H. Essell, MD, who is a leading authority on blood and marrow stem cell transplants. Dr. Essell is a national expert and author who is leading the CAR-T program for The US Oncology Network as its Medical Director of Cellular Therapies. Dr. Essell also serves as the Medical Director of the Blood Cancer Center at The Jewish Hospital – Mercy Health and as a principal investigator for OHC blood cancer clinical trials.
Dr. Broun, CAR-T E. Randolph Broun, MD, is a leading expert in the treatment of blood cancers. Dr. Broun is well-known for his advocacy work regarding payment reform and his outspoken support for community oncology practices and their patients.
Dr. Faber, CAR-T Edward A. Faber, Jr., DO, MS, is a nationally known, published leader in the treatment of blood cancers who specializes in the treatment of multiple myeloma. He is actively involved in clinical research and serves as principal investigator for OHC multiple myeloma clinical trials.
Dr. Ohlmayer, CAR-T Miguel Islas-Ohlmayer, MD, is a leader in the treatment of blood cancers and specializes in blood and marrow stem cell transplantation. He is actively involved in cancer research and serves as principal investigator for OHC lymphoma clinical trials.

 

Location:

OHC Kenwood
4777 E. Galbraith Road, Suite 320*
Cincinnati, Ohio 45236
*Located in The Jewish Hospital – Mercy Health

For more information about CAR-T, please call OHC at 1-800-710-4674.

CAR-T Clinical Trials at OHC

Not all patients diagnosed with a blood cancer experience a response from traditional treatments. Others aren’t eligible for treatments due to other medical conditions they have. For these patients, OHC is one of only four adult cancer groups in Ohio to offer chimeric antigen receptor T-cell therapy (CAR-T) for adult cancer patients, a revolutionary treatment that’s changing the world’s approach to cancer.

OHC has been treating patients with aggressive blood cancers with CAR-T for two years. Of those, almost half have experienced remission, offering a viable option where there was once no hope. OHC has expanded the use of CAR-T to more patients through its nationally-recognized clinical trials and research program.

CAR-T Clinical Trial 17006: For cancer patients with additional complex health conditions.
In Ohio, available only at OHC: This trial is for patients whose B-cell non-Hodgkin’s lymphoma didn’t respond to chemotherapy and they are not eligible for a stem cell transplant due to other medical conditions, such as impaired kidney function, impaired cardiac function, age or another condition. “Since this particular CAR-T treatment has fewer side effects, we believe it could be ideal for blood cancer patients who have other health issues or are older,” said OHC’s James H. Essell, MD, who is a national expert and author on CAR-T and serves as a principal investigator for OHC blood cancer clinical trials. This trial will also evaluate the administration of the treatment in an outpatient setting. Learn more.

CAR-T Clinical Trial 17007: CAR-T administered in an outpatient setting.
In Ohio, available only at OHC: This clinical trial is evaluating the administration of CAR-T in an outpatient setting. “This particular CAR-T treatment has shown to be less harsh with fewer side effects, so we believe it can be given in an outpatient setting instead of being admitted to a hospital. That would be a great benefit and cost savings for the patient,” said Dr. Essell. Learn more.

CAR-T Clinical Trial CTL019H2301 (BELINDA): CAR-T as a second line of treatment.
In the Cincinnati region, available only at OHC: The standard of care for patients with diffuse large B-cell lymphoma starts with chemotherapy. Next, a blood and marrow transplant is performed if there is no response to the chemotherapy or the cancer returns (relapse). If the cancer still doesn’t respond, then CAR-T is offered. This clinical trial is evaluating the use of CAR-T after chemotherapy relapse to determine its effectiveness compared to a transplant. Learn more.

Coming in 2020: Bispecific T-cell Engager (BiTE)
OHC will be one of a very select group of cancer groups selected to participate in clinical trials for the next generation of adoptive cell immunotherapy called bispecific T cell engager, or BiTE. BiTE is an innovative immunotherapy approach that could ultimately be used on more patients with more types of cancer including solid tumors. BiTEs form a link between T cells in the body’s immune system and tumor cells. The belief is this therapy will be capable of penetrating tumor tissue and provide your T-cells access to kill the cancer cells in your body. This approach has the potential to be another game-changer in cancer care.

Frequently Asked Questions About CAR-T

The following are frequently asked questions about CAR-T:

Q: How does CAR-T therapy work?
CAR-T is a type of immunotherapy that stimulates the body’s immune system to fight cancer. It uses genetically engineered immune T-cells to recognize specific proteins on tumor cells.

  • Thousands of T-cells are extracted from the patient and reengineered in a lab to produce special receptors on their surface that fight and kill cancer cells.
  • The reengineered cells are multiplied until there are millions and then infused back into the patient.
  • The cells continue to then multiply on their own in the patient’s body. These cells will recognize and kill cancer cells and help guard against recurrence.

Q: Who is eligible for CAR-T therapy?
CAR-T provides another cancer treatment option when standard treatments are not effective. Adult patients with relapsed or refractory large B-cell lymphoma who have failed two or more types of cancer therapy may be eligible. CAR-T clinical trials may be available for other blood cancers or solid tumors. If you are interested in CAR-T, please call OHC at 1-800-710-4674.

Q: Why is CAR-T therapy limited to certain blood cancers?
To date, the U.S. Food and Drug Administration (FDA) has approved CAR T-cell therapy for adult patients with certain types of non-Hodgkin lymphoma. OHC is conducting multiple clinical trials to test CAR-T therapies for other types of cancer.

Q: Are telemedicine consults available for CAR-T therapy?
In unique circumstances, OHC blood and marrow transplant specialists may offer a telemedicine consult to assess a patient’s eligibility.

Q: Where is CAR-T therapy available?
CAR-T is provided by OHC’s blood and marrow transplant specialists at the OHC Kenwood office. Patients who are eligible for CAR-T treatment and live outside the Cincinnati area may be able to schedule a consult with our CAR-T transplant experts via telemedicine.

Q: Why doesn’t my oncologist provide CAR-T therapy?
OHC’s transplant experts worked diligently to meet the rigorous criteria set by the Food and Drug Administration (FDA) in order to offer this revolutionary treatment, which is why OHC is one of only four adult cancer groups in Ohio to offer CAR-T to adults with cancer. It’s another example of OHC’s ongoing commitment to bringing leading-edge treatments to patients in the region.

Q: How can I enroll in a CAR-T clinical trial?
All patients are welcome to meet with a member of the OHC research team to learn more about CAR-T clinical trials and help you determine if a CAR-T clinical trial is right for you. Call 1-800-710-4674 to speak with a team member or request an appointment.

Q: Will insurance cover CAR-T therapy?
OHC’s team of financial navigators will help you verify coverage.

Q: How can I learn more about CAR-T therapy?
If you would like to learn more about CAR-T, click Request An Appointment or call OHC at 1-800-710-4674 and ask to speak with someone about CAR T-cell therapy.